Attached files
| file | filename |
|---|---|
| EX-31.1 - EX-31.1 - STEMLINE THERAPEUTICS INC | a18-1093_1ex31d1.htm |
| EX-32.2 - EX-32.2 - STEMLINE THERAPEUTICS INC | a18-1093_1ex32d2.htm |
| EX-32.1 - EX-32.1 - STEMLINE THERAPEUTICS INC | a18-1093_1ex32d1.htm |
| EX-31.2 - EX-31.2 - STEMLINE THERAPEUTICS INC | a18-1093_1ex31d2.htm |
| EX-21.1 - EX-21.1 - STEMLINE THERAPEUTICS INC | a18-1093_1ex21d1.htm |
| 10-K - 10-K - STEMLINE THERAPEUTICS INC | a18-1093_110k.htm |
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) Registration Statement (Form S-8 No. 333-188115) pertaining to Stemline Therapeutics, Inc. 2012 Equity Incentive Plan and Stemline Therapeutics, Inc. Amended and Restated 2004 Employee, Director and Consultant Stock Plan,
(2) Registration Statement (Form S-8 No. 333-206303) pertaining to Stemline Therapeutics, Inc. 2015 Employee Stock Purchase Plan,
(3) Registration Statement (Form S-8 No. 333-211784) pertaining to Stemline Therapeutics, Inc. 2016 Equity Incentive Plan,
(4) Registration Statement (Form S-3 No. 333-219794) of Stemline Therapeutics, Inc. and,
(5) Registration Statement (Form S-8 No. 333-219796) pertaining to Stemline Therapeutics, Inc. 2016 Equity Incentive Plan;
of our report dated March 16, 2018, with respect to the financial statements of Stemline Therapeutics, Inc. included in this Annual Report (Form 10-K) of Stemline Therapeutics, Inc. for the year ended December 31, 2017.
/s/ Ernst & Young LLP
Stamford, Connecticut
March 16, 2018